Life-threatening Acute Respiratory Failure in Children: to Breathe or Not to Breathe Spontaneously, That's the Question
Overview
- Phase
- Phase 4
- Intervention
- Neuromuscular Blocking Agents
- Conditions
- ARDS
- Sponsor
- University Medical Center Groningen
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- the cumulative respiratory morbidity score 12 months after PICU discharge, adjusted for confounding by age, gestational age, family history of asthma and/or allergy, season in which questionnaire was filled out and parental smoking
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
Paediatric acute respiratory distress syndrome (ARDS) is a manifestation of severe, life-threatening lung injury. Care for paediatric patient is mainly supportive and based on what works in adults and personal experiences, including the use of mechanical ventilation. However, differences in lung physiology and immunology between (young) children and adults suggests that adaptation of adult practices into paediatrics may not be justified. A study in adults with severe ARDS showed that early use of neuromuscular blocking agents (NMBA) improved 90-day survival and increased time off the ventilator without increasing muscle weakness. It is unknown if this is also true for paediatric ARDS
Investigators
Martin Kneyber
Chief, division of paediatric critical care medicine / Project leader
University Medical Center Groningen
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Rocuronium 1 mg/kg i.v.
Neuromuscular blocking agent
Intervention: Neuromuscular Blocking Agents
Isotonic saline
Intervention: Isotonic saline
Outcomes
Primary Outcomes
the cumulative respiratory morbidity score 12 months after PICU discharge, adjusted for confounding by age, gestational age, family history of asthma and/or allergy, season in which questionnaire was filled out and parental smoking
Time Frame: 12 months after PICU discharge